Product
osilodrostat
1 clinical trial
1 indication
Indication
Cushing's syndromeClinical trial
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With OsilodrostatStatus: Completed, Estimated PCD: 2023-11-16